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Comparative study of in situ deposit formation in active and passive
Heymann nephritis. Direct binding of antibodies to fixed glomerular
antigens is the principal mechanism of subepithelial immune deposit
formation in experimental membranous nephropathy induced by injec-
tion of heterologous antibody to rat Fx1A (passive Heymann nephritis,
PHN). In actively induced Heymann nephritis (autologous immune
complex nephritis, AICN) the role of this in situ mechanism as opposed
to circulating immune complex deposition has been debated. To exam-
ine this question we studied the deposit-forming characteristics of rat
IgG eluted from AICN kidneys and compared the results to those
obtained with heterologous (sheep) anti-FxlA IgG. We made the
following observations: (1) AICN eluate IgG binds in vitro to proximal
tubular brush borders and capillary walls of isolated glomeruli by
immunofluorescence. Furthermore, 1251 AICN eluate IgG binds specifi-
cally to isolated glomeruli (AICN eluate IgG > 8 x control IgG). (2)
After a single intravenous injection of 125J AICN eluate IgG, antibody
continued to accumulate slowly in glomeruli over 48 hr. This pattern of
antibody uptake closely resembles that previously described by us as
unique for heterologous anti-Fx1A. (3) Heterologous anti-Fx1A ap-
peared to competitively inhibit the glomerular binding of AICN eluate
IgG. When glomeruli containing increasing amounts of in viva deposit-
ed 125J heterologous antibody were isolated and incubated with a fixed
quantity of 'i AICN eluate IgG, an inverse relationship between the
binding of the two antibodies was observed (r =
—0.573, P < 0.01). (4)
Specific glomerular binding of AICN eluate IgG was observed in paired-
label studies using the isolated perfused kidney (IPK). This confirms
previous experiments in the IPK using heterologous antisera and
demonstrates the capacity of AICN eluate IgG to form glomerular
deposits in situ under relatively physiologic conditions. We conclude
that antibodies eluted from AICN glomeruli demonstrate deposit-
forming characteristics very similar to those of heterologous anti-Fx1A
antibodies in vitro and in vivo. Both antibodies produce subepithelial
deposits in viva and appear to bind to similar antigenic sites in the
glomerular capillary wall. These results support the contention that in
AICN, subepithelial immune deposit formation probably occurs by the
same in situ mechanism previously demonstrated in PHN.
Une étude comparative de Ia formation de dépôts immuns in situ dans Ia
néphrite de Heymann active et passive. La liaison directe d'anticorps a
des antigenes glomérulaires fixes est le mécanisme principal de Ia
formation de dépôts immuns sous-épithéliaux dans Ia nephrite extra-
membraneus expérimentale induite par l'injection d'anticorps hétéro-
logues a des rats FxIA (nephrite passive de Heymann, PHN). Dans la
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néphrite de Heymann induite activement (nephrite a immuns complexes
autologues, AICN) le role de ce mécanisme in situ, par opposition au
dépôt d'immuns complexes circulants, est débattu. Afin d'examiner
cette question, nous avons étudié les caractéristiques de formation de
depots d'IgG de rats élués a partir de reins d'AICN et nous avons
compare les résultats a ceux obtenus avec des IgG anti-FxlA hétéro-
logues (mouton). Nous avons fait les observations suivantes: (1) En
immunofluorescence, l'IgG éluée a partir d'AICN se lie in vitro aux
bordures en brosse tubulaires proximales et aux parois capillaires de
glomerules isolés. En outre, d l'éluat IgG d'AICN 1251 se lie specifique-
ment aux glomerules isolés (IgG éluée de l'AICN > 8 fois IgG contrOle).
(2) Après une injection intraveineuse unique d'éluat IgG de 125J AICN,
l'anticorps continuait a s'accummuler lentement dans les glomérules au
bout de 48 hr. Ce type de captation d'anticorps ressemble de près a
celui préalablement décrit par nous comme étant propre a l'anti-FxlA
hetérologue. (3) Il est apparu que anti-Fx1A heterologue inhibait
compétitivement Ia liaison glomerulaire de l'IgG éluée d'AICN. Quand
des glomérules contenant des quantites croissantes d'anticorps hétéro-
logues 1251 déposés in viva étaient isolés et incubés avec une quantith
fixe d'IgG éluée d'AICN 1311 une relation inverse entre Ia liaison des
deux anticorps était observée (r =
—0,573, P < 0,01). (4) Une lesion
glomerulaire specifique de l'IgG éluée d'AICN a été observée dans des
etudes avec double marquage utilisant un rein perfuse isolé (IPK). Cela
confirme des experiences antérieures avec l'IPK utilisant des anti-
serums heterologues, et démontre Ia capacité de l'IgG éluée d'AICN de
former des depots, glomerulaires in situ dans des conditions relative-
ment physiologiques. Nous concluons que les anticorps élués a partir de
glomerules d'AICN possèdent les caractéristiques de formation de
depots trés similaires celles d'anticorps anti-FxlA héterologues in
vitro et in vivo. Les deux anticorps produisent des depOts sous-
epitheliaux in vivo et se lient a des sites antigéniques identiques dans les
parois capillaires glomerulaires. Ces résultats confirment l'idée que
dans l'AICN, Ia formation de depOts immuns sous-épitheliaux se
produit probablement par le mhme mécanisme in situ prealablement
démontré dans la PHN.
In membranous nephropathy granular deposits of IgG and
complement are localized along the outer portion of the glomer-
ular capillary wall by immunofluorescence (IF) and exclusively
in the subepithelial space by electron microscopy (EM) l, 2j.
The experimental model which most closely resembles this
disease is autologous immune complex nephropathy (AICN), or
Heymann nephritis, induced in rats by immunization with an
antigen derived from the brush border of proximal tubular
epithelial cells (Fx1A) [3—51. Recent studies of the mechanism
of subepithelial immune deposit formation have utilized the
passive Heymann nephritis (PHN) model in which deposits,
indistinguishable morphologically from those in AICN, can be
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produced more rapidly by the passive intravenous administra-
tion of heterologous antibody to Fx lA [6—8]. Similar deposits
are also produced by ex vivo [71 or isolated kidney [8] perfusion
with the 7S IgG fraction of antibody to tubular antigen, demon-
strating that subepithelial immune deposits in the PHN model
can form in situ by the binding of free heterologous antibody to
a fixed glomerular antigen which is apparently cross-reactive
with some constituent of tubular brush border. Although both
the heterologous anti-Fx1A antibody used to induce PHN and
homologous antibody from the circulation or kidneys of AICN
rats have been shown to bind to isolated glomeruli in vitro [9—
11] form deposits in the isolated perfused kidney [8, 12] and
localize in the subepithelial space by immunoultrastructural
techniques [10, 11], the question of whether membranous
deposits in actively immunized AICN rats form in situ or result
instead from circulating immune complex trapping as suggested
by others [13, 14] remains unresolved.
To address this issue we have compared the deposit-forming
characteristics of heterologous anti-Fx1A and eluted AICN
antibodies in several systems. In previous studies we utilized
the heterologous antibody to rat tubular antigen to define the
kinetics of glomerular antibody binding in PHN in vivo [9],
document specific binding to isolated glomeruli in vitro [9], and
demonstrate in situ subepithelial immune deposit formation in
the isolated perfused rat kidney [8]. In this paper, similar kinetic
analyses, in vitro binding experiments, and isolated perfused
kidney studies have been done with antibody eluted from AICN
rat kidneys and results compared to those obtained previously
with the heterologous antibody. Moreover, the capacity of the
heterologous and homologous antibodies to bind to the same
antigenic site(s) in normal rat glomeruli has been evaluated. The
results demonstrate a remarkable similarity in the deposit-
forming characteristics of heterologous and homologous anti-
bodies and document the capacity of AICN eluate IgG to
produce in situ deposit formation. These findings support the
hypothesis that glomerular subepithelial immune deposits in
AICN result from in situ deposit formation rather than from
trapping circulating immune complexes.
Methods
Preparation of reagents
AICN eluate JgG. AICN was induced in male Lewis rats
weighing 60 to 120 g (Charles-River Breeding Laboratories,
Wilmington, Massachusetts) by rear footpad injection of 3.0mg
of Fx1A in 0.2 ml of an emulsion made of equal parts of
incomplete Freund' s adjuvant (Difco Laboratories, Detroit,
Michigan), containing 4.0 mglml of pulverized Mycobacterium
tuberculosis (Difco Laboratories), and 0.02 M phosphate-buff-
ered saline, pH 7.4, (PBS) containing 30 mg/ml of proximal
tubular brushborder antigen [5]. Fx1A was prepared from fresh,
saline-perfused Sprague-Dawley rat renal cortices according to
the method of Edgington, Glassock, and Dixon [13] and lyophi-
lized prior to use.
Rats were sacrificed approximately 10 weeks after immuniza-
tion when all surviving animals had proteinuria exceeding 50
mg124 hr, and 214 kidneys were removed. Representative
kidneys were studied by direct IF (see below) for deposition of
rat IgG and complement (C3). Within 24 hr of nephrectomy,
AICN kidneys were chopped into small pieces, suspended in
PBS at 4° C and homogenized for approximately 15 sec in a
Waring blender. The homogenate was washed repeatedly in
PBS at 4° C until the protein concentration of the supernatant
was constant (15 times). The homogenate was then suspended
in 0.02 M citrate buffer, pH 3.2, and stirred gently at room
temperature for 4.25 hr [15]. After removing the supernatant,
the remaining homogenate was further eluted with 0.02 M
citrate buffer at pH 2.5 for an additional 4.25 hr. The superna-
tants were isolated by centrifugation at 6000 rpm for 30 mm
followed by titration to pH 7.2 with 0.3 N NaOH. After
extensive dialysis against PBS the eluates were concentrated by
ultrafiltration in a stirred cell (Model 202, Amicon Corp.,
Lexington, Massachusetts) using a PM 30 Diaflo ultrafilter
(Amicon Corp.). The concentrated supernatants from each
elution were combined after it was determined that both had
antibrushborder activity by indirect IF on normal rat kidneys
(see below).
IgG was isolated from the concentrated AICN eluate by ion
exchange chromatography on DEAE Sephadex (Pharmacia
Fine Chemicals, Inc., Piscataway, New Jersey) using 0.01 M
sodium phosphate buffer followed by application of a linear
sodium chloride gradient to 0.3 N. The monomeric fraction
(150,000 daltons) of AICN eluate IgG was isolated by gel
filtration chromatography on size-calibrated columns of Sepha-
dex G-l50 or Sephacryl S-200 (Pharmacia Fine Chemicals,
Inc.).
AICN eluate was characterized by micro-Ouchterlony and
immunoelectrophoresis in 1% agarose gel using goat anti-serum
to whole rat serum and rat IgG (Miles Biochemicals, Elkhart,
Indiana). Indirect IF of AICN eluate on cryostat sections of
normal rat kidney was also performed (see below). Five days
after a rat was injected with approximately 3 mg of AICN eluate
IgG, renal tissue was examined by direct IF for rat IgG and rat
C3, and EM was performed.
Control acid-treated normal rat IgG. To simulate elution
conditions lyophilized normal rat IgG (Miles Biochemicals) was
reconstituted in PBS at approximately 2 mg/mI, and one volume
was mixed with 10 volumes of 0.02 M citrate buffer, pH 3.2, and
stirred at room temperature for 4.25 hr. After neutralization and
extensive dialysis against PBS, the rat IgG was concentrated to
approximately 2 mg/mI and stored at 4° C. The monomeric
fraction of acid-treated normal rat IgG was isolated by gel
filtration on Sephacryl S-200 (Pharmacia Fine Chemicals, Inc.).
Heterologous Anti-FxJA IgG. Sheep anti-rat Fx1A was pre-
pared by repeatedly immunizing adult male sheep with FxlA in
complete Freund's adjuvant (Difco Laboratories) over a 2-
month period [9]. Two weeks after the last immunization serum
was collected, it was heat inactivated (56° C, 30 mm) and
absorbed with pooled rat serum, leukocytes, erythrocytes and
platelets. The lgG fraction was isolated from a 50% ammonium
sulfate precipitate by ion-exchange chromatography on DEAE-
Sephadex (Pharmacia Fine Chemicals, Inc.). The preparation
and characteristics of this antibody have been previously de-
scribed in detail [9].
Heterologous anti-rat glomerular basement membrane
(GBM) IgG. Antibody to rat GBM was prepared by immunizing
sheep with whole rat glomeruli [16]. IgG isolation and absorp-
tion were performed exactly as described for heterologous anti-
Fx1A IgG. Ten milligrams of anti-GBM IgG administered to
normal rats induced 4+ linear staining for IgG on the GBM, no
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extra-glomerular deposits by IF, and urine protein excretion of
about 200 mg/day in the 24-hr period after injection.
Experimental design
Kinetics of AICN eluate IgG disappearance from blood and
deposition in glomeruli. After administration of AICN eluate
IgG to rats, the disappearance from blood and the accumulation
of antibody in glomeruli were studied at intervals over a 5-day
period [9]. Eighteen rats were each injected intravenously with
143.4 g of radiolabelled AICN eluate IgG. Groups of three rats
were sacrificed at 1, 4, 24, and 48 hr, 4 days, and 5 days after
antibody administration. Just prior to sacrifice, 100 .d of blood
from each rat were obtained to determine the blood IgG
concentration. The three rats that were killed at 5 days had 100
p.l of blood taken at each time interval. The initial blood
concentration of IgG for each animal was calculated by dividing
the administered dose of IgG by the rat's blood volume (esti-
mated at 7% of body weight) [17].
Total kidney antibody binding was measured after kidneys
were perfused with heparinized saline [9]. To determine the
quantity of antibody specifically bound in glomeruli in each
animal, glomeruli were isolated from freshly perfused kidneys
by differential sieving and centrifugation as previously de-
scribed [9]. The glomeruli from each animal were counted
visually, and their radioactivity was measured [9]. Glomerular
antibody binding (GAb) for each rat was calculated from the
equation: (GAb agI2 kidneys) = CPM in glomeruli x 76,000
divided by the number of glomeruli x specific activity of
antibody, where 76,000 represents the number of glomeruli in
two rat kidneys [9, 18, 19]. Previous studies have shown that no
detectable contamination with serum is present in glomeruli
prepared by this method [9]. Delivery of antibody (pg/unit time)
was calculated by multiplying RBF times the area under the
curve formed by plotting blood concentration versus time. RBF
was taken to be 5.4 mI/mm/kidney [20], and it was assumed that
the trace doses of antibody used in the study did not affect RBF.
In vitro binding of eluate IgG to normal rat glomeruli. The
ability of monomeric AICN eluate IgG to bind to isolated
glomeruli in vitro was compared to that of monomeric acid-
treated normal rat IgG. Normal rat glomeruli were isolated from
saline perfused kidneys as described above and suspended in
PBS. Four 500-tl aliquots containing equal numbers of glomer-
uli were mixed with either 15 .tg of 1251 AICN eluate IgG or 15
ig 125j acid-treated normal rat IgG. The final concentration of
IgG was 27 g/ml for AICN eluate IgG and 29 g/ml for acid-
treated normal rat IgG. The suspensions were mixed thoroughly
and incubated at 37° C. After 21 hr, the glomeruli were washed
repeatedly with PBS, and glomerular bound radioactivity was
measured. The results are expressed as micrograms of IgG
bound/l03 glomeruli.
Glomeruli incubated with AICN eluate IgG were also exam-
ined by direct IF to compare the localization of rat antibody
with that of heterologous anti-Fx1A IgG described previously
[9]. Sheep anti-rat GBM IgG and acid-treated normal rat IgG
served as positive and negative controls. AICN antibody IgG
(100 pg), 100 ig of acid-treated normal rat IgG, or 500 sg of
anti-GBM IgG were added to tubes containing equal aliquots of
freshly isolated rat glomeruli suspended in Hank's solution (pH
7.4 with 500 U aqueous penicillin, 500 g streptomycin and 2 g
bovine serum albumin (BSA) per deciliter) and incubated at
37° C for 3 hr. The glomeruli were washed with PBS, suspended
in Tissue Tek II (Lab Tek Products, Miles Laboratories, Inc.,
Napaville, Illinois), and snap-frozen in dry ice. Four-micron
cryostat sections of each pellet were prepared, stained with
fluorescein-conjugated goat anti-rat IgG or rabbit anti-sheep
IgG, and examined [211.
Effect of in vivo deposits of heterologous anti-FxJA on the in
vitro binding of AICN eluate IgG. To evaluate whether AICN
eluate IgG and heterologous anti-Fx1A IgG bind to the same
antigen, the ability of in vivo bound heterologous anti-Fx1A
IgG to inhibit the subsequent in vitro binding of AICN eluate
IgG was examined. To confirm the specificity and sensitivity of
the method, the capacity of in vivo bound heterologous anti-
Fx1A IgG to inhibit the in vitro binding of the same heterolo-
gous anti-Fx1A IgG was also assessed. 1251 heterologous anti-
Fx1A IgG was administered intravenously to ten rats in sub-
nephritogenic doses ranging from 0.8 to 26.6 mg. Four days
later glomeruli were isolated from each animal and suspended in
Hank's solution with 2% BSA. Aliquots of 5000 glomeruli from
each animal were placed in four 10 x 75 mm tubes. Four control
tubes contained 5000 normal rat glomeruli each. Twenty-five
micrograms of 1311 AICN eluate IgG were added to two tubes of
glomeruli from each animal and to two control tubes, and 100
tg of 1311 heterologous anti-Fx1A IgG were added to the
remaining tubes. After incubation at 37° C for 21 hr glomeruli
were washed, counted for 125J and 131J and glomerular antibody
binding in each tube was calculated and plotted.
Isolated perfused kidney studies. Isolated kidneys were per-
fused according to the method of Ross, Epstein, and Leaf [22]
as we previously reported [8]. The perfusate consisted of 6.5 to
6.8 g % BSA in 100 ml Krebs-Henseleit high bicarbonate buffer,
pH 7.4. GFR was measured after 5 mm of perfusion using '4C
inulin. Only kidneys with GFR exceeding 0.5 ml/min were used
in experiments. After the addition of 133 to 140 .tg of monomer-
ic 1251 AICN eluate IgG and 113 to 121 jtg of monomeric 1311
acid-treated normal rat IgG to the perfusate, three kidneys were
perfused in separate experiments for 120 mm. During this time,
perfusion pressure was maintained at 100 to 110 mm Hg, and
temperature was maintained at 37° C. Perfusate was obtained at
the end of the study to determine protein-bound radioactivity.
Immediately following perfusion, the kidneys were flushed with
approximately 250 ml of PBS under similar perfusion pressures,
and radioactivity in the whole kidneys was measured to calcu-
late total kidney antibody binding [9]. Glomeruli were isolated
from each kidney, and the quantity of antibody specifically
bound was calculated using the equation: specific glomerular
125! cpm = total glomerular 125! cpm—['311 glomerular cpm x
(1251 perfusate cpm/ 131J perfusate cpm)] [23]. The results are
expressed as micrograms of antibody bound/38,000 glomeruli.
Glomerular antibody binding/ 1000 g of antibody delivered to
the kidney/hour was calculated as described above.
As a measure of nonspecific protein binding, in two experi-
ments the radioactivity was also measured in the millipore
filters which were used in the perfusion system.
Radiolabelling
AICN eluate IgG, acid-treated normal rat IgG, and heterolo-
gous anti-FxlA IgG were labelled with either 1251 or 131j (New
England Nuclear, Boston, Massachusetts) using the chloramine
T method [24]. After labelling, 5 to 10 mg aliquots of homolo-
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acid-treated normal rat IgG [261. Differences were regarded as
significant when P was <0.05. Regression analysis and determi-
nation of the correlation coefficient for data relating in vivo
glomerular-bound heterologous anti-Fx1A IgG to in vitro
glomerular binding of AICN eluate IgG and heterologous anti-
Fx1A were determined by standard methods [261. All values are
expressed as mean 1 SD unless otherwise stated.
Other procedures
Protein concentration of IgG purified from AICN eluate and
commercial rat IgG (Miles Biochemicals) was measured by UV
absorption at 280 nm using an extinction coefficient of 1.4.
Purified sheep IgG was measured using the biuret method.
Results
Characterization of AICN eluate
Fig. 1. Indirect IF of AICN eluate IgG (1 mg/mI) on normal rat kidney
stained for rat IgG. Strongly positive brushborder staining and weakly
positive granular staining along the glomerular capillary wall are
present. (x400)
gous nonantibody IgG were added prior to the removal of free
I25j or 131J by ion-exchange chromatography on AG1-X8 (Bio-
Rad Laboratories, Richmond, California) and either extensive
dialysis against PBS or gel filtration on G-25 Sephadex (Phar-
macia Fine Chemicals Inc.). The preparations were concentrat-
ed and stored at —70° C prior to use. Measurement of the
trichloroacetic acid (TCA) precipitability and specific activity
of individual reagents were made immediately prior to use; 79 to
95% of cpm were protein bound. Specific activities of the
individual reagents ranged from 2.9 >< 102 to 2.5 x l0 cpm/g
IgG. Radioactivity was determined in a well type auto gamma
spectrometer (Nuclear Chicago, Model 1085, Chicago, Illinois).
Tissue processing, immunofluorescence and electron
microscopy
Renal tissue was obtained by wedge biopsy under ether
anesthesia and snap-frozen in dry ice-isopentane, Cryostat
sections fixed in ether-ethanol were stained using techniques
and controls described elsewhere [9, 211. IF staining used the
fluorescein isothiocyanate conjugated IgG fractions of mono-
specific rabbit anti-sheep IgG and goat anti-rat IgG (N.L.
Cappel Laboratories Inc., Cochranville, Pennsylvania), and
rabbit anti-rat C3 [25]. IF was evaluated on a fluorescence
microscope (Leitz Ortholux II) equipped with a Ploempak 2.2
vertical fluorescence illuminator (E. Leitz Inc., Rockleigh,
New Jersey). EM studies of the 5-day renal biopsy specimen
from the rat that received 5 mg AICN eluate were performed
generously by Dr. Helmut Rennke, Harvard Medical School,
Boston, Massachusetts. Tissue for EM was fixed in Kar-
novsky's solution and post-fixed in 1% osmium tetroxide fol-
lowed by en bloc fixation in uranyl acetate for 30 mm before
dehydration and embedding in EPON 812. Thin sections were
stained on the grid with lead citrate and examined on an
electron microscope (Phillips 201, J.V. Philip GloeslampenFa-
brieken, Einhoven, The Netherlands).
Statistical analysis
The Student's t test for paired data was used to analyze the
results of in vitro glomerular binding of AICN eluate IgG and
Ten-week AICN kidneys studied by IF had 3 to 4+ finely
granular deposits of rat IgG and 1 to 2+ deposits of rat C3 in a
membranous pattern as described previously [51. Elution of 214
10-week AICN rat kidneys yielded about 45 mg of IgG. IgG
was the only serum protein identifiable in the AICN eluate by
immunoelectrophoresis and micro-Ouchterlony before and af-
ter ion-exchange chromatography. Indirect IF of AICN eluate
on cryostat sections of normal rat kidney demonstrated strongly
positive reactivity with tubular brush border. At 1 mg/mi IgG
the indirect IF titer on tubular brush border was 1:100. Weakly
reactive granular staining was also seen along the glomerular
capillary walls with undiluted eluate (Fig. 1). Renal biopsy
performed 5 days after intravenous administration of 5 mg of
AICN eluate to a normal rat demonstrated 2 to 3+ diffuse
granular deposits of IgG along the glomerular capillary wall
similar to deposits seen in AICN kidneys (Fig. 2A). Staining for
rat C3 was negative. Numerous electron dense deposits were
present in the subepithelial space, predominantly in slit pore
regions (Fig. 2B).
Kinetics of AICN eluate IgG disappearance from blood and
deposition in glomeruli
After the intravenous administration of 143.4 ,ug of AICN
eluate IgG, there was a rapid decline in blood concentration
with 19.6% of the calculated level at time 0 remaining at 1 hr
(Fig. 3). After 48 hr less than 1% of the antibody administered
was still present in the circulation. The blood level continued to
decline gradually from days 2 to 5.
The kinetics of glomerular antibody deposition are also
shown in Figure 3. Accumulation of antibody in glomeruli was
145 ng (0.1% of the administered dose) at 1 hr and continued to
increase to a maximum of 325 ng (0.23% of the administered
dose) at 48 hr. From 48 hr through day 5, when blood antibody
levels were barely detectable, no significant change in the
quantity of antibody deposited in glomeruli could be demon-
strated. The quantity of AICN eluate IgG bound in vivo in
glomeruli per 1000 g of AICN eluate IgG delivered to the
kidney in the first hour after administration of antibody was
0.037 0.006 gig. Glomerular antibody binding in vivo repre-
sented 22% of antibody bound in the whole kidney at 48 hr.
In vitro binding of AICN eluate IgG to normal glomeruli
After a 21-hr incubation of normal rat glomeruli with either 15
ig of AICN eluate IgG or 15 g of acid-treated normal rat IgG,
a
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demonstrated (Fig. 4). After the addition of 25 of AICN
eluate IgG to tubes containing 5,000 glomeruli with increasing
quantities of in vivo bound heterologous anti-Fx1A IgG,
glomerular antibody binding of AICN eluate IgG declined from
0.81 to 0.31 g per 5,000 glomeruli when in vivo bound
heterologous anti-FxIA increased from 0 to 2.6 g (r =
—0.573,
y = 0.52 — 0.064x,P <0.01, Fig. 4). The validity of this method
for demonstrating the reactivity of the two antibodies with a
similar antigen was validated by the inverse correlation also
observed between the in vivo binding of 1251 heterologous anti-
Fx1A IgG (0 to 2.6 g/5000 glomeruli) and the subsequent in
vitro binding of the same heterologous anti-FxIA labelled with
131J (N = 10, r = —0.722, y = 6.06 — 1.34x, P < 0.01).
Isolated perfused kidney studies
In all three isolated perfused kidney studies specific binding
of AICN eluate IgG (0.35, 0.29, and 0.26 igI38,000 glomeruli)
was demonstrated in glomeruli by paired labeled studies after
120 mm of perfusion. In all three experiments the binding of
acid-treated normal rat IgG was less than 3% of the binding of
AICN eluate IgG. Millipore filters removed from the perfusion
system contained small quantities of both AICN eluate IgG and
normal rat IgG, and there was no specific binding of either.
Because of the small quantity of eluate used, no attempt could
be made to localize the site of deposition in the perfused kidney
by IF or EM.
The quantity of AICN eluate IgG bound in glomeruli per 1000
g of AICN eluate IgG delivered to the kidney over 2 hr was
0.246 0.05 g, and glomerular-bound eluate IgG represented
12.2 2.8% of the amount bound in the whole kidney.
Discussion
Fig. 2. A kidney biopsy specimen from a rat 5 days after intravenous
administration of AICN eluate IgG. A Direct IF of granular deposits of
rat IgG in a diffuse pattern along glomerular capillary walls. (x400) B
Electron micrograph of subepithelial electron dense deposits located
primarily in slit pore regions. (x 30,000) Abbreviations are: US, urinary
space; Ep, epithelial cell; Cap, capillary lumen.
the binding of AICN eluate IgG was eightfold greater than that
of normal rat IgG. Following the incubation period, 4.73 0.09
tg of AICN eluate IgG bound per 10,000 normal rat glomeruli,
whereas only 0.57 0.04 g of normal rat IgG bound (P <
0.001). This represented 24.3% binding of the AICN eluate IgG
and 2.9% binding of the normal rat IgG.
Although AICN eluate IgG could be demonstrated to bind
specifically to normal rat glomeruli by indirect IF, no attempt
was made to further define the site of in vitro binding.
Effect of in vivo deposition of heterologous anti-FxJA IgG on
in vitro binding of AICN eluate IgG
When isolated rat glomeruli containing progressively greater
quantities of in vivo bound heterologous anti-Fx1A IgG were
incubated with a fixed amount of AICN eluate IgG in vitro, an
inverse correlation between in vivo and in vitro binding was
The quantitative studies reported here provide convincing
evidence that the glomerular antibody deposited in AICN rats
can produce subepithelial deposits by an in situ mechanism
similar to that already demonstrated for heterologous antibody
in PHN. These results confirm and extend several isolated
previous observations related to the same issue. Thus, Sugisaki
et al [27] showed that the glomerular lesion of AICN could be
transferred only by the 7S fraction of IgG antibody in the
circulation of AICN rats. Fleuren, Grond, and Hoedemaeker
[10] and Neale and Wilson [lii have demonstrated subepithelial
localization of AICN eluate IgG in normal rat glomeruli using
ultrastructural immunoperoxidase techniques; Neale and Wil-
son showed that AICN eluate IgG could bind specifically to
isolated normal rat glomeruli [11]; and Makker and Moorthy
[12] induced in situ deposit formation at several sites in the
glomerulus by cx vivo perfusion of AICN eluate into an
ischemic rat kidney. However, the present studies, to our
knowledge, represent the most systematic and quantitative
comparison of the deposit-forming characteristics of AICN
eluate IgG compared to heterologous antibody to rat Fx1A and
provide what appears to be convincing evidence that the two
antibodies can form deposits by similar mechanisms.
In the kinetic studies reported here with eluate IgG, glomeru-
tar antibody deposition occurs slowly following intravenous
injection with maximal antibody deposition at 48 hr, a pattern
closely resembling one previously described for heterologous
IgG in which deposit formation increased steadily over a 5-day
period despite rapidly falling blood IgG levels [9]. The longer
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period of antibody deposition in the latter study presumably
reflected the slower disappearance of heterologous IgG from
the circulation compared to eluted rat IgG which had largely
disappeared by 48 hr. Several explanations for this indolent
pattern of deposit formation with the two antibodies might be
offered. In vitro binding studies demonstrate that ample antigen
is present normally to immediately bind the amounts of anti-
body deposited in vivo over 48 hr. Thus, the unique kinetics of
glomerular deposition observed with both of these antibodies
presumably reflects restricted access of antibody to antigenic
sites in vivo probably due to interposition of the proximal layers
of the size- and charge-selective glomerular filtration barrier
between circulating antibody and the site of deposit formation
(and presumably antigen localization) [28—30]. This suggestion
is supported by other studies from our laboratory demonstrat-
ing that both antibody size [31] and charge [321 are important
determinants of the rate of antibody deposition in the subepithe-
hal space.
The in vitro binding studies using AICN eluate IgG demon-
strate that normal rat glomeruli contain sufficient antigen to
directly bind quantities of IgG comparable to those deposited
after in vivo injection without invoking other mechanisms of
deposit formation. The precise site of in vitro antibody binding
was not addressed in this study, although IF studies by us and
immuno-ultrastructural studies by others [10, 111 clearly show
that it is on the glomerular capillary wall in a distribution similar
to that of glycosaminoglycan-containing fixed anionic sites in
the lamina rara externa [33, 34]. Our in vitro binding results,
which confirm those reported by Neale and Wilson [11], are
similar to our earlier in vitro studies using heterologous anti-
body [91, and provide further support for the contention that
both heterologous antibody and eluate IgG can form deposits by
an in situ mechanism.
The competitive-binding studies provide additional evidence
that both heterologous and eluted antibodies bind directly to
similar sites within the glomerular capillary wall. These studies
also demonstrate a significant negative correlation between
heterologous IgG bound in glomeruli in vivo and the subsequent
in vitro binding of eluate IgG that suggests both antibodies may
be directed against shared antigenic determinants in the glomer-
ular basement membrane. Although the experimental design
ensured that all in vivo glomerular bound heterologous antibody
was in subepithelial deposits and hence comparable to AICN
eluate IgG, which was presumably derived exclusively from
deposited antibody, several qualifications in the interpretation
of this data must be acknowledged. It is possible that in vitro
binding of eluate was reduced by steric hindrance, or alter-
ations in the GBM induced by the heterologous IgG deposited
earlier in vivo. However, since the quantity of heterologous
antibody deposited was insufficient to saturate antigenic sites
and not great enough to produce glomerular injury, this seems
unlikely. In addition it is likely that eluate IgG was of lower
avidity than heterologous lgG or autologous antibody circulat-
ing in animals with AICN, although this cannot be quantified
because antigen is unavailable in pure form to study. All of
these factors may have contributed to the greater inhibition by
heterologous antibody of in vitro binding of itself as compared
to in vitro binding of the eluate. While these reservations
preclude a definitive statement claiming that identical antigenic
specificity has been demonstrated in heterologous antibody and
eluate, the competitive-binding results taken in the context of
the rest of this study seem most consistent with this conclusion.
Finally, the ability of AICN eluate to produce deposits in situ
was documented further by the paired-label studies in the
isolated perfused kidney. These studies confirm other experi-
ments we have carried out with AICN eluate provided by Neale
et al [35]. The present IPK studies differ in two respects from
our earlier studies using heterologous anti-Fx1A IgG [8]. Only
trace-labelled quantities of IgG were used thus precluding
localization of deposit formation by IF and EM as was done
before. A recirculating, rather than single pass perfusion system
was also used which allows the theoretical possibility of tubular
antigen entering the perfusate to form circulating immune
complexes. The latter possibility seems unlikely, since our
Fig. 3. The disappearance kinetics of 125J
AICN eluate IgG from the blood of rats (solid
line) and simultaneous accumulation of anti-
body IgG in glomeruli (broken line) after in-
travenous administration of 143 .4 g of AICN
eluate IgG. The number of animals sampled at
each interval is in parentheses.
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Fig. 4. The relationship of in vitro binding of 25 jxg of AICN eluate IgG
to glomeruli isolated from rats 5 days after the intravenous administra-
lion of heterologous anti-FxIA IgG and containing varying quantities
of heterologous antibody bound in vivo.
previous studies using heterologous antibody showed no appar-
ent differences in deposit formation between recirculating and
single-pass systems [81. With regard to the localization of
deposits, Fleuren, Grond, and Hoedemaeker [10], using an ex
vivo perfusion system, haye shown that perfusion of rat kidneys
with eluate IgG produced only subepithelial immune deposits.
However, Makker and Moorthy [121, using a less well charac-
terized AICN eluate perfused ex vivo into an ischemic rat
kidney, have noted mesangial and vascular localization of IgG
by IF.
In our studies only 12% of the eluate IgG that bound
specifically in isolated perfused kidneys was in glomeruli, while
in vivo only 22% of renal binding was glomerular. These data
suggest that some specific binding of eluate IgG does occur at
extra-glomerular sites in the isolated perfused kidney. More-
over, in this study the amount of glomerular binding of AICN
eluate IgG per amount delivered in the first 2 hr appeared
quantitatively greater in the isolated perfused kidney than in
vivo. This is also consistent with the suggestion of Makker and
Moorthy [12] that the rate of specific glomerular antibody
binding may be enhanced in the isolated perfused kidney
compared to in vivo deposit formation. The factors responsible
for this phenomenon are unclear.
In the PUN model, the ability of heterologous 7S anti-FxIA
to produce in situ subepithelial immune deposits (which are
indistinguishable from those in AICN) by reacting with a fixed
antigen in the normal rat glomerulus is now well established [7—
91. Our findings indicate that the IgG antibody deposited in
glomeruli in AICN rats also demonstrates the same unique
kinetics of glomerular deposition in vivo that we have previous-
ly shown with the heterologous anti-Fx1A IgG used to induce
PHN [9]. It binds readily to normal glomeruli in vitro as the
heterologous antibody does, and the heterologous and AICN
eluate IgG apparently bind to similar or adjacent antigenic sites
in glomeruli. IgG eluted from AICN rat kidneys also forms
glomerular deposits in situ in the isolated perfused kidney as
previously shown with heterologous antibody [8]. We believe
that the findings outlined in this study now justify the sugges-
tion that in situ deposit formation is probably the principle
mechanism by which subepithelial immune deposits develop in
both AICN and PHN.
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